Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTSee What the ACVIM Recommends for Certain Types of Canine CHFSafe, effective treatment that's approved by the FDA for management of certain types of canine CHF. + Learn More